Physician profile
Luke A Ellerman
NPI 1386206795
$1,047.78
in general payments reported to CMS, 2019-2025
10 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $325 · 2022: $82.79 · 2023: $218 · 2024: $200 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $588.31 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Beta Bionics, INC. | $150.46 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novo Nordisk INC | $143.30 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Corcept Therapeutics | $40.79 | 2021 | |
| Tandem Diabetes Care, INC. | $25.19 | 2022 | |
| Welch Allyn | $24.38 | 2021 | |
| Amgen INC. | $20.67 | 2024 | Tepezza |
| Lilly USA, LLC | $19.57 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.47 | 2024 | Recorlev |
| Sanofi-Aventis U.S. LLC | $15.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Ellerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.